Eular recommendations for the management of rheumatoid arthritis - Differences between versions from 2013 and 2010;Doporučení EULAR pro léčbu revmatoidní artritidy - Rozdíly mezi verzí 2013 a 2010

Ceska Revmatologie

Volumn 22, Issue 2, 2014, Pages 70-80

  Pavelka, P ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

EULAR recommendations; Rheumatoid arthritis; Therapy

Indexed keywords

ABATACEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TOFACITINIB;

ARTICLE; HUMAN; MONOTHERAPY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL (TOPIC); DELPHI STUDY; METHODOLOGY; ORGANIZATION;

EID: 84922777663     PISSN: 12107905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR re commendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013: doi:10.1136/annrheumclis-2013-204573.
2. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010:69(6):964-975.
3. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013:72(10):1613-20.
4. Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2013, v tisku.
5. Klarenbeek NB, Koevoets R, Van der Heijde DM, Gerards AH, Ten WS, Kerstens PJ et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011:70(10):1815-1821.
6. Gaujoux-Viala C, Gossec L, et al. Efficacy of conventional synthetic DMARDs, glucocorticoids and tofacitinib - a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2013: submitted.
7. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495-505.
8. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009;68(7):1105-1112.
9. De Jong PH, Hazes JM, Barendregt PJ, Huisman M, Van ZD, Van der Lubbe PA et al. Induction therapy with a combination of DM ARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013;72(1):72-78.
10. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64(9):2824-2835.
11. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E et al. Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med 2012;156(5):329-339.
12. Canalis E, Mazziotti G, Giustina A, Bilezikian JP: (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328.
13. Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379(9827):1712-20.
14. Genovese MC, McKay JD, Nasonov EL et al. Interleukin 6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80.
15. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
16. Gabay C, Emery P, Van VR, Dikranian A, Alten R, Pavelka K et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381(9877):1541-1550.
17. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367(6):508-519.
18. Kavanaugh A, Emery P, Felischmann RM, et al.: Withrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: esults of a phase 4, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2012;51(Suppl 3): iii27.
19. Smolen JS, Nash P, Durez P, Hall S, Llivanova E, Irazoque-Palazuelos F et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381(9870):918-929.
20. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Ann Rheum Dis 2011;70:404-413.